KDR and neoplasm: Notably, several multi-kinase inhibitors, including dovitinib (FLT-3/c-Kit, FGFR1/3, and VEGFR) and cediranib (VEGFR, FIT1/4, and c-KIT), showed significantly high anti-tumor activities in HGSCs (P = 2.92 × 10−02 and P = 3.98 × 10−03 for dovitinib and cediranib, respectively).